Doranidazole
| Code | Size | Price |
|---|
| TAR-T31566-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31566-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T31566-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Dornidazole (PR-000350, PR-350, RP-343, PR-69) is an effective radiosensitizer for hypoxic cells with the potential for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer.
CAS:
161903-10-2
Formula:
C8H13N3O6
Molecular Weight:
247.207
Purity:
0.98
SMILES:
OC[C@@H](O)[C@H](CO)OCn1ccnc1[N+]([O-])=O
References
1. Yasui H, Asanuma T, Kino J, Yamamori T, Meike S, Nagane M, Kubota N, Kuwabara M, Inanami O. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. BMC Cancer. 2013 Mar 8;13:106. doi: 10.1186/1471-2407-13-106. PubMed PMID: 23496909; PubMed Central PMCID: PMC3599813.
2. Murata R, Tsujitani M, Horsman MR. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol. 2008 Jun;87(3):331-8. doi: 10.1016/j.radonc.2008.03.002. Epub 2008 Mar 28. PubMed PMID: 18375007.
3. Karasawa K, Sunamura M, Okamoto A, Nemoto K, Matsuno S, Nishimura Y, Shibamoto Y. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol. 2008 Jun;87(3):326-30. doi: 10.1016/j.radonc.2008.02.007. Epub 2008 Mar 14. PubMed PMID: 18342968.
4. Zhang L, Gong A, Ji J, Wu Y, Zhu X, Lv S, Lv H, Sun X. The radiosensitizing effect of doranidazole on human colorectal cancer cells exposed to high doses of irradiation. BMC Cancer. 2007 Oct 6;7:188. PubMed PMID: 17919337; PubMed Central PMCID: PMC2082041.